Working Together to 'Stay in the Game'
Pharma Giants Combine HIV Pipelines into New Company
By Jennifer Boggs
Friday, April 17, 2009
Despite rumors (or perhaps hopes) that GlaxoSmithKline plc might follow recent news from Pfizer Inc. and Merck & Co. Inc. with its own mega-merger, the London-based pharma firm has opted for a more modest venture, pooling its HIV portfolio with Pfizer's in an unusual display of cooperation between pharmaceutical competitors. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.